Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Crossref DOI link: https://doi.org/10.1007/s00415-015-7970-6
Published Online: 2015-12-08
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Braune, Stefan
,
Lang, M.
Bergmann, A.
License valid from 2015-12-08